Novartis AG Registered Shares

NOVN: XSWX (CHE)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|&@LOCK|r>jLOCK|$Rn^!LrL

Novartis: Back-to-Back Phase 3 Failures for Pelacarsen and Del-Desiran Send Shares Sliding

After the market close on Sept. 4, Novartis reported that cardiometabolic drug pelacarsen missed its primary endpoint in its Lp(a)HORIZON trial. Separately, on Sept. 8, rare disease drug del-desiran missed its primary endpoint in the HARBOR trial in myotonic dystrophy type 1.

Sponsor Center